LnRiLWZpZWxke21hcmdpbi1ib3R0b206MC43NmVtfS50Yi1maWVsZC0tbGVmdHt0ZXh0LWFsaWduOmxlZnR9LnRiLWZpZWxkLS1jZW50ZXJ7dGV4dC1hbGlnbjpjZW50ZXJ9LnRiLWZpZWxkLS1yaWdodHt0ZXh0LWFsaWduOnJpZ2h0fS50Yi1maWVsZF9fc2t5cGVfcHJldmlld3twYWRkaW5nOjEwcHggMjBweDtib3JkZXItcmFkaXVzOjNweDtjb2xvcjojZmZmO2JhY2tncm91bmQ6IzAwYWZlZTtkaXNwbGF5OmlubGluZS1ibG9ja311bC5nbGlkZV9fc2xpZGVze21hcmdpbjowfQ==
IC50Yi1maWVsZFtkYXRhLXRvb2xzZXQtYmxvY2tzLWZpZWxkPSJiNWY3MWI2ZGI3MzBiMzU3MGVmOTUwZWU3NjUwNzZlMSJdIGEgeyB0ZXh0LWRlY29yYXRpb246IG5vbmU7IH0gW2RhdGEtd29vY29tbWVyY2Utdmlld3MtbGlzdC1hdHRyaWJ1dGVzPSJjNDAyOTU5NmUzY2QzZjg0NDM3ZTgxNzVmYTEzZDgwNiJdIC53b292aWV3cy1saXN0LWF0dHJpYnV0ZXMgeyBib3JkZXI6IDFweCBzb2xpZCByZ2JhKCAyMTQsIDIxNCwgMjE0LCAwLjU1ICk7d2lkdGg6IDEwMCU7IH0gW2RhdGEtd29vY29tbWVyY2Utdmlld3MtbGlzdC1hdHRyaWJ1dGVzPSJjNDAyOTU5NmUzY2QzZjg0NDM3ZTgxNzVmYTEzZDgwNiJdIC53b292aWV3cy1saXN0LWF0dHJpYnV0ZXMgdHI6bnRoLWNoaWxkKGV2ZW4pIHRoLCBbZGF0YS13b29jb21tZXJjZS12aWV3cy1saXN0LWF0dHJpYnV0ZXM9ImM0MDI5NTk2ZTNjZDNmODQ0MzdlODE3NWZhMTNkODA2Il0gLndvb3ZpZXdzLWxpc3QtYXR0cmlidXRlcyB0cjpudGgtY2hpbGQoZXZlbikgdGQgeyBiYWNrZ3JvdW5kLWNvbG9yOiByZ2JhKCAyNDIsIDI0MiwgMjQyLCAwLjUgKTsgfSBbZGF0YS13b29jb21tZXJjZS12aWV3cy1saXN0LWF0dHJpYnV0ZXM9ImM0MDI5NTk2ZTNjZDNmODQ0MzdlODE3NWZhMTNkODA2Il0gLndvb3ZpZXdzLWxpc3QtYXR0cmlidXRlcyB0aCwgW2RhdGEtd29vY29tbWVyY2Utdmlld3MtbGlzdC1hdHRyaWJ1dGVzPSJjNDAyOTU5NmUzY2QzZjg0NDM3ZTgxNzVmYTEzZDgwNiJdIC53b292aWV3cy1saXN0LWF0dHJpYnV0ZXMgdGQgeyBwYWRkaW5nOiA1cHggMTBweCA1cHggMTBweDtib3JkZXI6IDFweCBzb2xpZCByZ2JhKCAyMTQsIDIxNCwgMjE0LCAwLjU1ICk7IH0gW2RhdGEtd29vY29tbWVyY2Utdmlld3MtbGlzdC1hdHRyaWJ1dGVzPSJjNDAyOTU5NmUzY2QzZjg0NDM3ZTgxNzVmYTEzZDgwNiJdIC53b292aWV3cy1saXN0LWF0dHJpYnV0ZXMgdHIgdGgud29vY29tbWVyY2UtcHJvZHVjdC1hdHRyaWJ1dGVzLWl0ZW1fX2xhYmVsLCBbZGF0YS13b29jb21tZXJjZS12aWV3cy1saXN0LWF0dHJpYnV0ZXM9ImM0MDI5NTk2ZTNjZDNmODQ0MzdlODE3NWZhMTNkODA2Il0gLndvb3ZpZXdzLWxpc3QtYXR0cmlidXRlcyB0ciB0aC53b292aWV3cy1saXN0LWF0dHJpYnV0ZXMtaXRlbV9fbGFiZWwgeyBmb250LXdlaWdodDogYm9sZDt0ZXh0LWFsaWduOiBsZWZ0OyB9IGJvZHkud29vY29tbWVyY2UgIFtkYXRhLXdvb2NvbW1lcmNlLXZpZXdzLWFkZC10by1jYXJ0PSJjMjhmMzc0YWVjMmI0Y2YyZjBjNjg4MThhOTE5MGZlOCJdIGZvcm0uY2FydCAud29vdmlld3MtdGVtcGxhdGUtcXVhbnRpdHkgaW5wdXRbdHlwZT1udW1iZXJdIHsgcGFkZGluZzogMC41ZW07d2lkdGg6IDYwcHg7bGluZS1oZWlnaHQ6IDM2cHg7IH0gYm9keS53b29jb21tZXJjZSBkaXYucHJvZHVjdCAgW2RhdGEtd29vY29tbWVyY2Utdmlld3MtYWRkLXRvLWNhcnQ9ImMyOGYzNzRhZWMyYjRjZjJmMGM2ODgxOGE5MTkwZmU4Il0gZm9ybS5jYXJ0IC53b292aWV3cy10ZW1wbGF0ZS1xdWFudGl0eSBpbnB1dFt0eXBlPW51bWJlcl0geyBwYWRkaW5nOiAwLjVlbTt3aWR0aDogNjBweDtsaW5lLWhlaWdodDogMzZweDsgfSAudGItZmllbGRzLWFuZC10ZXh0W2RhdGEtdG9vbHNldC1ibG9ja3MtZmllbGRzLWFuZC10ZXh0PSJhNjIzYTY5YzRmYzJhYTBiYjA5NzA3YmI1OGYxZDk3ZiJdIHsgZm9udC1zaXplOiAxMnB4OyB9IC50Yi1maWVsZHMtYW5kLXRleHRbZGF0YS10b29sc2V0LWJsb2Nrcy1maWVsZHMtYW5kLXRleHQ9ImE2MjNhNjljNGZjMmFhMGJiMDk3MDdiYjU4ZjFkOTdmIl0gcCB7IGZvbnQtc2l6ZTogMTJweDsgfSAgLnRiLWZpZWxkW2RhdGEtdG9vbHNldC1ibG9ja3MtZmllbGQ9Ijg5YTE2ZTZkZDg3NDM2ZTE3MGE3OTVhZDRhZDM3NDE1Il0gYSB7IHRleHQtZGVjb3JhdGlvbjogbm9uZTsgfSBAbWVkaWEgb25seSBzY3JlZW4gYW5kIChtYXgtd2lkdGg6IDc4MXB4KSB7ICBib2R5Lndvb2NvbW1lcmNlICBbZGF0YS13b29jb21tZXJjZS12aWV3cy1hZGQtdG8tY2FydD0iYzI4ZjM3NGFlYzJiNGNmMmYwYzY4ODE4YTkxOTBmZTgiXSBmb3JtLmNhcnQgLndvb3ZpZXdzLXRlbXBsYXRlLXF1YW50aXR5IGlucHV0W3R5cGU9bnVtYmVyXSB7IHBhZGRpbmc6IDAuNWVtO3dpZHRoOiA2MHB4O2xpbmUtaGVpZ2h0OiAzNnB4OyB9IGJvZHkud29vY29tbWVyY2UgZGl2LnByb2R1Y3QgIFtkYXRhLXdvb2NvbW1lcmNlLXZpZXdzLWFkZC10by1jYXJ0PSJjMjhmMzc0YWVjMmI0Y2YyZjBjNjg4MThhOTE5MGZlOCJdIGZvcm0uY2FydCAud29vdmlld3MtdGVtcGxhdGUtcXVhbnRpdHkgaW5wdXRbdHlwZT1udW1iZXJdIHsgcGFkZGluZzogMC41ZW07d2lkdGg6IDYwcHg7bGluZS1oZWlnaHQ6IDM2cHg7IH0gICB9IEBtZWRpYSBvbmx5IHNjcmVlbiBhbmQgKG1heC13aWR0aDogNTk5cHgpIHsgIGJvZHkud29vY29tbWVyY2UgIFtkYXRhLXdvb2NvbW1lcmNlLXZpZXdzLWFkZC10by1jYXJ0PSJjMjhmMzc0YWVjMmI0Y2YyZjBjNjg4MThhOTE5MGZlOCJdIGZvcm0uY2FydCAud29vdmlld3MtdGVtcGxhdGUtcXVhbnRpdHkgaW5wdXRbdHlwZT1udW1iZXJdIHsgcGFkZGluZzogMC41ZW07d2lkdGg6IDYwcHg7bGluZS1oZWlnaHQ6IDM2cHg7IH0gYm9keS53b29jb21tZXJjZSBkaXYucHJvZHVjdCAgW2RhdGEtd29vY29tbWVyY2Utdmlld3MtYWRkLXRvLWNhcnQ9ImMyOGYzNzRhZWMyYjRjZjJmMGM2ODgxOGE5MTkwZmU4Il0gZm9ybS5jYXJ0IC53b292aWV3cy10ZW1wbGF0ZS1xdWFudGl0eSBpbnB1dFt0eXBlPW51bWJlcl0geyBwYWRkaW5nOiAwLjVlbTt3aWR0aDogNjBweDtsaW5lLWhlaWdodDogMzZweDsgfSAgIH0g
ZY10-156
Category: Antibodies A-Z
Technetium (99Mtc) Nofetumomab Merpentan (IL3RA/CD123) – Research Grade Biosimilar
0.1 mg
$644.00
9999 in stock
Product Description
| Size | 0.1 mg |
|---|---|
| Host | |
| Species Reactivity | |
| Applications | |
| Clonality | Recombinant Monoclonal |
| Class | Neuroscience |
| Conjugation | Unconjugated |
Dataseet – Request by Email at zinfo@zyagen.com